Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

How Will PSMAddition Impact the Management of Prostate Cancer?

European urology focus·2026

Same author

Top advances of the year: Radiopharmaceutical therapy for prostate cancer.

Cancer·2026

Same author

PSMA-PET Total Tumor Volume Response: Ready for Prime Time or a Work in Progress?

European urology·2026

Same author

Temporal Trends in the Frequency of Concomitant Cancer and Cerebrovascular Disease Diagnoses in the United States.

Neurology. Clinical practice·2026

Same author

PD-1/PD-L1 for prostate cancer: from clinical trials to practice.

Expert review of clinical pharmacology·2026

Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Pediatric Urological Emergencies at a Regional Hospital in Burkina Faso: A Series of 28 Cases.

Advances in urology·2026

Same journal

Clinical Characteristics and Diagnostic Pathways of Emphysematous Cystitis in a University Hospital: A Retrospective Observational Study.

Advances in urology·2026

Same journal

Correction to "Prognostic Value of Serum Cystatin C for Predicting Contrast-Induced Nephropathy in Elderly Individuals Aged Over 80 years".

Advances in urology·2026

Same journal

Are Big Prostates a Challenge? Correlation Between Prostate Volume and Detection Rate in Fusion Biopsy of the Prostate.

Advances in urology·2026

Same journal

Sacrocolpopexy Using Polyvinylidene Fluoride Mesh: A Systematic Review and Meta-Analysis.

Advances in urology·2026

Same journal

Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence.

Advances in urology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate-specific membrane antigen-based therapeutics.

Naveed H Akhtar¹, Orrin Pail, Ankeeta Saran

¹Division of Hematology and Medical Oncology, Weill Cornell Medical College, 525 E. 68th Street, Box 403, New York, NY 10065, USA.

Advances in Urology

|August 4, 2011

Summary

This summary is machine-generated.

Targeting prostate cancer (PC) with advanced anti-prostate-specific membrane antigen (PSMA) therapies, including radioimmunotherapy and antibody-drug conjugates, shows promise for improving treatment outcomes in men with advanced disease.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Related Experiment Videos

Last Updated: May 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Area of Science:

Oncology
Immunotherapy
Radiopharmaceuticals

Background:

Prostate cancer (PC) is a leading cause of cancer-related death in men, with limited systemic treatment options for advanced stages.
Prostate-specific membrane antigen (PSMA) is a highly specific target overexpressed on prostate cancer cells.
Previous anti-PSMA antibodies were less effective; newer J591 antibodies target the external domain of PSMA on viable cells.

Purpose of the Study:

To review the development and clinical application of anti-PSMA therapies for prostate cancer.
To highlight the potential of novel immunotherapies and radioimmunoconjugates in treating advanced prostate cancer.
To explore strategies for optimizing patient selection and treatment combinations.

Main Methods:

Review of clinical trials and preclinical studies involving anti-PSMA monoclonal antibodies, including J591.
Analysis of radiolabeled J591 (radioimmunotherapy) and anti-PSMA antibody-drug conjugates.
Investigation of PSMA-targeted immunotherapy approaches.

Main Results:

Radiolabeled J591 demonstrates accurate tumor targeting, safety, and efficacy in clinical studies.
Ongoing trials with (177)Lu-J591 aim to enhance therapeutic profiles and patient selection.
Anti-PSMA antibody-drug conjugates are in early-phase clinical trials, showing therapeutic potential.

Conclusions:

Anti-PSMA therapies, particularly radioimmunotherapy with J591 and antibody-drug conjugates, represent a promising advancement in prostate cancer treatment.
Targeting PSMA offers a highly specific approach to combatting prostate cancer, including in cases of biochemical relapse.
Future research focuses on optimizing these therapies, combining them with chemotherapy, and preventing metastatic progression.